RxDoctor Payments Data

Jee-Hong Kim, MD

Otolaryngology · Walnut Creek, CANPI 1629423140

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $98,088 of the $130,768 with a category attached, or 75.0%. Regeneron Healthcare Solutions, Inc. accounts for 60.5% of it on its own, with 18 other manufacturers making up the rest. 2025 is the largest year on record at $79,147, more than ten times the $123 reported in 2019. Among otolaryngology clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$130,768in general payments, 2019–2025

Across 290 payments — averaging $450.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Regeneron Healthcare Solutions, Inc.$79K
  • GSK$32K
  • Sanofi$10K
  • Regeneron$3K
  • Inspire Medical Systems, Inc.$2K
  • Medtronic$1K
  • plus $3K from 13 others

What the payments were for

  • Consulting fees$9,7507%
  • Speaking & faculty fees$98,08875%
  • Travel & lodging$12,72110%
  • Food & beverage$10,0888%
  • Education$1220%

General payments by program year

19
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$130,768 in reported general payments places this provider in the 95th percentile of 1,021 otolaryngology providers in California.

See all otolaryngology providers in California

Medicare billing

Part B allowed, 2024
$79,861
Medicare patients
93
Services billed
353

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Dupixent PenDupilumab12$44,905
Azelastine Hcl35$917
Ipratropium Bromide52$770
Doxycycline Hyclate15$162

Paid to pharmacies, not to this prescriber.

Other otolaryngology in Walnut Creek

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →